Cargando…
Estimated vaccine effectiveness against SARS-CoV-2 Delta and Omicron infections among health care workers and the general adult population in Norway, August 2021 – January 2022
BACKGROUND: Health care workers (HCW) have a higher exposure to SARS-CoV-2 virus than other professionals and to protect both HCW and patients, HCW have been prioritized for vaccination against SARS-CoV-2 in many countries. Estimating the COVID-19 vaccine effectiveness among HCW is important to prov...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169571/ https://www.ncbi.nlm.nih.gov/pubmed/37211454 http://dx.doi.org/10.1016/j.vaccine.2023.05.022 |
_version_ | 1785039066219151360 |
---|---|
author | Langlete, Petter Tesli, Martin Veneti, Lamprini Starrfelt, Jostein Elstrøm, Petter Meijerink, Hinta |
author_facet | Langlete, Petter Tesli, Martin Veneti, Lamprini Starrfelt, Jostein Elstrøm, Petter Meijerink, Hinta |
author_sort | Langlete, Petter |
collection | PubMed |
description | BACKGROUND: Health care workers (HCW) have a higher exposure to SARS-CoV-2 virus than other professionals and to protect both HCW and patients, HCW have been prioritized for vaccination against SARS-CoV-2 in many countries. Estimating the COVID-19 vaccine effectiveness among HCW is important to provide recommendations to protect risk groups. METHODS: We estimated vaccine effectiveness against SARS-CoV-2 infections using Cox proportional hazard models among HCW with comparisons in the general population, from 1 August 2021 to 28 January 2022. Vaccine status is specified as a time-varying covariate and all models incorporated explicit time and were adjusted for age, sex, comorbidities, county of residence, country of birth, and living conditions. Data from the adult Norwegian population (aged 18–67 years) and HCW workplace data (as registered 1 January 2021) were collated from the National Preparedness Register for COVID-19 (Beredt C19). RESULTS: Vaccine effectiveness was higher for Delta than for the Omicron variant in HCW (71 % compared to 19 %) as well as in non-HCW (69 % compared to −32 %). For the Omicron variant a 3rd dose provides significantly better protection against infection than 2 doses in both HCW (33 %) and non-HCW (10 %). Further, HCW seem to have better vaccine effectiveness than non-HCW for the Omicron, but not for the Delta variant. CONCLUSIONS: Vaccine effectiveness were comparable between HCW and non-HCW for the delta variant, but significantly higher in HCW than non-HCW for the omicron variant. Both HCW and non-HCW got increased protection from a third dose. |
format | Online Article Text |
id | pubmed-10169571 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | The Author(s). Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101695712023-05-10 Estimated vaccine effectiveness against SARS-CoV-2 Delta and Omicron infections among health care workers and the general adult population in Norway, August 2021 – January 2022 Langlete, Petter Tesli, Martin Veneti, Lamprini Starrfelt, Jostein Elstrøm, Petter Meijerink, Hinta Vaccine Article BACKGROUND: Health care workers (HCW) have a higher exposure to SARS-CoV-2 virus than other professionals and to protect both HCW and patients, HCW have been prioritized for vaccination against SARS-CoV-2 in many countries. Estimating the COVID-19 vaccine effectiveness among HCW is important to provide recommendations to protect risk groups. METHODS: We estimated vaccine effectiveness against SARS-CoV-2 infections using Cox proportional hazard models among HCW with comparisons in the general population, from 1 August 2021 to 28 January 2022. Vaccine status is specified as a time-varying covariate and all models incorporated explicit time and were adjusted for age, sex, comorbidities, county of residence, country of birth, and living conditions. Data from the adult Norwegian population (aged 18–67 years) and HCW workplace data (as registered 1 January 2021) were collated from the National Preparedness Register for COVID-19 (Beredt C19). RESULTS: Vaccine effectiveness was higher for Delta than for the Omicron variant in HCW (71 % compared to 19 %) as well as in non-HCW (69 % compared to −32 %). For the Omicron variant a 3rd dose provides significantly better protection against infection than 2 doses in both HCW (33 %) and non-HCW (10 %). Further, HCW seem to have better vaccine effectiveness than non-HCW for the Omicron, but not for the Delta variant. CONCLUSIONS: Vaccine effectiveness were comparable between HCW and non-HCW for the delta variant, but significantly higher in HCW than non-HCW for the omicron variant. Both HCW and non-HCW got increased protection from a third dose. The Author(s). Published by Elsevier Ltd. 2023-06-13 2023-05-10 /pmc/articles/PMC10169571/ /pubmed/37211454 http://dx.doi.org/10.1016/j.vaccine.2023.05.022 Text en © 2023 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Langlete, Petter Tesli, Martin Veneti, Lamprini Starrfelt, Jostein Elstrøm, Petter Meijerink, Hinta Estimated vaccine effectiveness against SARS-CoV-2 Delta and Omicron infections among health care workers and the general adult population in Norway, August 2021 – January 2022 |
title | Estimated vaccine effectiveness against SARS-CoV-2 Delta and Omicron infections among health care workers and the general adult population in Norway, August 2021 – January 2022 |
title_full | Estimated vaccine effectiveness against SARS-CoV-2 Delta and Omicron infections among health care workers and the general adult population in Norway, August 2021 – January 2022 |
title_fullStr | Estimated vaccine effectiveness against SARS-CoV-2 Delta and Omicron infections among health care workers and the general adult population in Norway, August 2021 – January 2022 |
title_full_unstemmed | Estimated vaccine effectiveness against SARS-CoV-2 Delta and Omicron infections among health care workers and the general adult population in Norway, August 2021 – January 2022 |
title_short | Estimated vaccine effectiveness against SARS-CoV-2 Delta and Omicron infections among health care workers and the general adult population in Norway, August 2021 – January 2022 |
title_sort | estimated vaccine effectiveness against sars-cov-2 delta and omicron infections among health care workers and the general adult population in norway, august 2021 – january 2022 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169571/ https://www.ncbi.nlm.nih.gov/pubmed/37211454 http://dx.doi.org/10.1016/j.vaccine.2023.05.022 |
work_keys_str_mv | AT langletepetter estimatedvaccineeffectivenessagainstsarscov2deltaandomicroninfectionsamonghealthcareworkersandthegeneraladultpopulationinnorwayaugust2021january2022 AT teslimartin estimatedvaccineeffectivenessagainstsarscov2deltaandomicroninfectionsamonghealthcareworkersandthegeneraladultpopulationinnorwayaugust2021january2022 AT venetilamprini estimatedvaccineeffectivenessagainstsarscov2deltaandomicroninfectionsamonghealthcareworkersandthegeneraladultpopulationinnorwayaugust2021january2022 AT starrfeltjostein estimatedvaccineeffectivenessagainstsarscov2deltaandomicroninfectionsamonghealthcareworkersandthegeneraladultpopulationinnorwayaugust2021january2022 AT elstrømpetter estimatedvaccineeffectivenessagainstsarscov2deltaandomicroninfectionsamonghealthcareworkersandthegeneraladultpopulationinnorwayaugust2021january2022 AT meijerinkhinta estimatedvaccineeffectivenessagainstsarscov2deltaandomicroninfectionsamonghealthcareworkersandthegeneraladultpopulationinnorwayaugust2021january2022 |